Ethanolamine Test

Most people with diabetes who keep their blood sugar in a healthy range still worry about the slow damage creeping through their eyes. A lower than expected level of this small molecule in the blood has been shown to flag the people most likely to develop diabetic retinopathy (eye damage caused by diabetes), sometimes with far more accuracy than the standard three month blood sugar average.

This is an emerging research marker rather than an established clinical test. Universally agreed cutpoints do not yet exist, but it is one of the clearer blood signals available for the membrane-building chemistry that shapes eye, kidney, brain, and metabolic health.

What Ethanolamine Does in Your Body

Ethanolamine is a small nitrogen-containing molecule, and it is also the starting point your cells use to build a major family of membrane fats called phosphatidylethanolamine (often shortened to PE) and ethanolamine plasmalogens (a type of membrane fat that is especially important in the brain). Every cell in your body relies on these fats to keep its outer wall flexible and functional.

Because ethanolamine is spent on membrane building, signaling, and related reactions, the amount floating in your blood reflects the balance between what your body is making, using, and recycling. A blood measurement captures the free, unbuilt form, which is different from the membrane-bound versions (PE and plasmalogens) that most of the downstream biology depends on. The two are connected, but they are not interchangeable.

Diabetic Retinopathy Risk

The strongest direct evidence for ethanolamine as a blood biomarker comes from people with well-controlled type 2 diabetes. In a study of 71 such patients, those with lower serum ethanolamine were far more likely to go on to develop diabetic retinopathy, the leading cause of blindness in working-age adults.

The gap in accuracy was striking. Ethanolamine separated future retinopathy cases from diabetics who would not develop eye damage with an area under the curve (a score of how well a test distinguishes two groups, where 1.0 is perfect and 0.5 is useless) of around 0.95 in discovery and 0.91 in validation. HbA1c (the three month blood sugar average used as the standard diabetes metric), by comparison, scored close to 0.5, meaning it could barely tell the two groups apart in this already well-controlled population.

What this means for you: if you have diabetes and your HbA1c looks fine, that number alone may miss the subset of people whose eyes are still quietly under threat. A low ethanolamine level does not prove retinopathy is coming, but it is a warning sign worth taking seriously, especially if you also have other risk factors like longstanding diabetes or family history of eye disease.

Metabolic Health and Insulin Resistance

Serum ethanolamine tends to run lower in people with obesity and type 2 diabetes than in healthy controls. In one metabolomics study of 85 adults, lower serum levels in these groups were interpreted as a signature of disturbed endocannabinoid signaling (a lipid-based messaging system tied to appetite and inflammation) and altered phospholipid metabolism, both of which connect back to insulin resistance.

Separate work looking at the gut side of this story found that people with obesity harbor fewer bacteria capable of breaking down ethanolamine, and that fecal ethanolamine correlates with BMI (body mass index). This points to a two-sided picture: gut handling of ethanolamine shifts with weight, and blood levels shift with metabolic state. The blood test does not directly measure what is happening in the gut, but it is part of the same pathway.

Kidney Function

Genetic analyses of more than fifty urinary metabolites have linked higher urinary ethanolamine to higher eGFR (estimated glomerular filtration rate, a measure of how much blood your kidneys filter per minute), suggesting a protective relationship with kidney function. Keep in mind this finding comes from urine measurements rather than blood, so it speaks to ethanolamine handling by the kidneys rather than to what a blood test directly captures. The two are related but not identical.

Neurodegenerative Disease

Serum ethanolamine shows up as part of a metabolite signature that distinguishes people with amyotrophic lateral sclerosis (a disease that destroys the nerves controlling muscle movement, often shortened to ALS) from healthy controls, with the combined panel reaching an area under the curve of about 0.898. Ethanolamine on its own is not a diagnostic test for ALS, but the finding fits a broader pattern in which disturbed phospholipid chemistry shows up across multiple nerve and brain diseases.

Postmortem brain research measuring ethanolamine plasmalogens (a related but different analyte, bound into membranes rather than floating free) has linked lower levels to worse cognition and dementia. Whether blood ethanolamine tracks these brain changes has not been directly confirmed in living humans. Treat the cognitive connection as suggestive rather than established.

Cancer Associations

Ethanolamine behaves differently in cancer tissue than in blood. In 106 pancreatic cancer samples, higher ethanolamine levels inside the tumor itself were linked to worse survival, and low tumor ethanolamine strongly identified long-term survivors. This is tumor biology, not a blood test, so do not over-read what your serum value means for cancer risk.

In lung cancer, specific phosphatidylethanolamine species (built-out versions of ethanolamine, not the free form the blood test measures) helped distinguish metastatic disease from multiple primary tumors with sensitivity above 90%. Again, this is a different analyte in a different clinical setting. The finding shows that ethanolamine chemistry is biologically important in cancer, but a routine blood ethanolamine level is not a cancer screening tool.

Putting the Different Findings Together

One of the confusing things about this biomarker is that low levels look bad in some settings (diabetes, metabolic disease) while high levels look bad in others (pancreatic tumor tissue, the serum profile seen in ALS). The resolution is that ethanolamine is not a simple good number or bad number marker. It is a chemistry indicator, and the same value can mean different things depending on what else is going on in your body and which tissue the sample came from.

The cleanest clinical takeaway so far is the diabetic retinopathy link, which is based on direct serum measurement in people with diabetes. Other associations, especially those built on tumor tissue, urine, or membrane-bound phospholipids, are biologically related but should not be read as if they were direct evidence about your blood value.

Reference Ranges

Ethanolamine does not have standardized clinical reference intervals, cutpoints, or guideline-based targets from professional societies. It is a research-grade measurement, and different labs using different methods may report different numbers for the same sample. No optimal range has been proposed for preventive or longevity use.

The most practical approach is to treat your first result as a personal baseline rather than as a score on a fixed scale. Compare future results to that baseline, within the same lab, using the same method. A meaningful downward trend in a person with diabetes is more informative than a single number in isolation.

Why One Reading Is Not Enough

Because standardized cutpoints do not yet exist and because ethanolamine is shaped by diet, gut microbes, and moment-to-moment metabolism, a single reading can be misleading. The real value of this test shows up over time. A trend moving steadily in one direction tells you more than any single snapshot, and it lets you see whether a change you are making to your health is actually registering in your chemistry.

A reasonable approach is to get a baseline, retest in three to six months if you are making meaningful changes to your diet, weight, or glycemic control, and then at least once a year after that. If you have diabetes that already looks well controlled on paper, a yearly check gives you a second lens on whether your eye risk is drifting.

What To Do With an Abnormal Result

A single unusual value should not drive a major clinical decision. Start by repeating the test a few weeks later, ideally through the same lab, to confirm the finding is real and not a measurement blip. If the pattern holds, the next move depends on your clinical context.

• If you have diabetes: low ethanolamine alongside a normal HbA1c is a reason to tighten eye surveillance, ideally with an ophthalmologist familiar with diabetic retinopathy, and to look hard at your metabolic control beyond the three-month average.
• If you are managing weight or insulin resistance: pair the result with fasting insulin, HbA1c, a lipid panel, and a liver panel to build a fuller picture. A single low ethanolamine adds texture; it does not replace those measurements.
• If you are tracking general health: use the value as a personal baseline rather than a diagnosis. Retest on a cadence that matches your goals, and pay more attention to the direction of change than to the number itself.
• If you are being evaluated for a neurological condition: this is research-grade territory. An abnormal result should prompt discussion with a specialist, not self-diagnosis.

When Results Can Be Misleading

Ethanolamine chemistry responds to food, gut bacteria, and overall metabolic state, so a few practical factors can distort a single reading.

• Recent meals: ethanolamine feeds into amino acid and phospholipid pathways, and a large protein-heavy or fat-heavy meal shortly before the draw can shift values. Blood is typically drawn fasting for amino acid panels.
• Gut state: significant changes in your gut microbes, including recent antibiotic use or gastrointestinal illness, can alter how much ethanolamine reaches your bloodstream.
• Specimen handling: free amino alcohols like ethanolamine are sensitive to how the blood sample is collected, spun, and stored. Results from different labs or methods may not be directly comparable.
• Assay variation: because no standardized clinical method is in widespread use, the same sample can yield different numbers across labs. Compare results within the same lab over time.